Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry, specifically recommending an "Accumulate" rating for both the pharmaceutical manufacturing and pharmaceutical services sectors [1][2]. Core Insights - Continuous attention is suggested on innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug industry is experiencing a high demand for assets, with multinational corporations showing greater interest than concerns over geopolitical risks [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Monthly Portfolio Performance - The report highlights a monthly portfolio for June 2025, including companies such as Jiangsu Heng Rui Medicine, Huadong Medicine, and Sichuan Kelun Pharmaceutical, among others [5][36]. - In May 2025, the portfolio achieved an average increase of 7.7%, outperforming the overall pharmaceutical index, which rose by 4.5% [11][37]. Market Performance - In May 2025, the pharmaceutical sector ranked first in performance, with notable sub-sectors like chemical raw materials (+10.5%) and chemical preparations (+9.6%) showing strong growth [20][37]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. International Market Comparison - The Hong Kong pharmaceutical sector outperformed the market with a rise of 7.8%, while the U.S. pharmaceutical sector underperformed, declining by 5.7% [38]. - The report identifies top-performing stocks in both markets, with significant gains in the Hong Kong sector and notable declines in the U.S. sector [38].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].

Group 1 - The A-share and Hong Kong stock markets saw a strong performance in the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) closing up 2.24%, ranking first among innovative drug ETFs and twelfth in the overall ETF market, with a trading volume exceeding 11 million yuan [1] - The Tianhong Innovative Drug ETF was launched in 2021 and tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - Key stocks in the ETF included Ruizhi Pharmaceutical, which rose over 13%, along with other notable gainers such as Tigermed, Hutchison China MediTech, Federal Pharmaceutical, and Huahai Pharmaceutical [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million and potential milestone payments of up to $1.93 billion [2] - The innovative drug sector is expected to continue being a primary focus for pharmaceutical investments, driven by increasing policy support and a shift from quantity and speed to quality and innovation in Chinese innovative drugs [4] - The number of original research drugs entering clinical stages in China has reached 704, surpassing the United States and positioning China as the global leader in this area [3]

本文摘自：2025年6月2日发布的 2025ASCO揭幕，持续推荐创新药 余文心 ，资格证书编号： S0880525040111 郑 琴 ，资格证书编号： S0880525040108 谈嘉程 ，资格证书编号： S0880523070004 更多国泰海通研究和服务 亦可联系对口销售获取 报告导读： 2025ASCO 揭幕，中国创新药资产继续在国际舞台上发光发热，持续推荐景 气度向上的创新药。 2025ASCO 揭幕，中国创新药资产继续在国际舞台上发光发热。 2025 年美国临床肿瘤学会（ ASCO ） 年会当地时间 5/30-6/3 在美国芝加哥举行。本次 ASCO 中国创新药资产的口头报告（ oral+rapid oral+LBA ）数量达 73 项，创历史新高 。经过十余年来的发展，中国创新药已走到国际舞台中央，一个 又一个交易额突破新高的海外 BD 反映了 MNC 对中国创新药资产的需求已远大于对地缘风险的担忧。随 着头部创新药企已经开始批量进入扭亏为盈的新发展阶段，中生代 Biotech 旗下优质资产迎来 BD 浪潮 开始密集出海，传统药企走出集采阴影、创新药业务进入兑现期迎来估值重估，中国创新药产业 ...

Group 1 - Public funds are adopting an "angel investor" strategy in the innovative drug sector, despite the high volatility and risks associated with drug development and approval processes [1][4] - The significant returns in the innovative drug sector are driven by overseas licensing and collaboration events, rather than traditional metrics like revenue and profit growth [2][5] - The top-performing funds in the market, such as the Huatai-PineBridge Hong Kong Advantage Fund, have achieved substantial returns, with a 71% increase this year, primarily through heavy investments in innovative drugs [2][7] Group 2 - Many innovative drug companies show poor financial indicators, with substantial net profit losses, yet public funds continue to invest heavily based on future potential rather than current performance [3][4] - Event-driven strategies, such as licensing agreements with multinational pharmaceutical companies, have significantly boosted stock prices in the innovative drug sector [5][6] - The expectation of financial recovery in the innovative drug sector is growing, with fund managers predicting a collective improvement in revenue and profitability starting from mid-2025 [7][8] Group 3 - The period from 2025 to 2028 is anticipated to be crucial for Chinese innovative drug companies, with many expected to enter a profitability phase, marking a potential turning point for the sector [8]

Core Viewpoint - The Hong Kong innovative pharmaceutical sector has gained significant traction in the capital market this year, with a notable performance of related ETFs, indicating strong investor interest and potential growth in the industry [3][5]. Group 1: Performance of ETFs - As of May 30, 2023, the top 17 cross-border ETFs in terms of returns are all related to Hong Kong pharmaceuticals, with annual returns exceeding 40% [3][5]. - Specific ETFs such as the Huatai-PB Hang Seng Innovative Drug ETF and the GF CSI Hong Kong Innovative Drug ETF have reported returns of 43.36% and 42.09% respectively [5]. - The total net inflow of funds into these ETFs has been substantial, with the Huatai-PB ETF seeing an increase of 19.78 million shares [5]. Group 2: Private Equity Interest - Private equity firms have shown a strong preference for newly listed ETFs, particularly in the sci-tech sector, with 104 private equity products appearing in the top ten holdings of 97 newly listed ETFs, holding a total of 1.783 billion shares [3][8]. - The sci-tech ETFs have attracted 32.02% of the total shares held by private equity, indicating a robust interest in high-growth potential sectors [8]. Group 3: Future Outlook for Innovative Pharmaceuticals - Industry experts express optimism regarding the investment potential in innovative pharmaceuticals, citing favorable policies and market conditions as catalysts for growth [4][6]. - The ongoing development of innovative drugs is supported by government initiatives, which aim to streamline approval processes and enhance market access [7][8]. - The increasing demand for innovative drugs is driven by an aging population and heightened health awareness, suggesting a sustainable growth trajectory for the sector [7][8]. Group 4: Free Cash Flow ETFs - Newly listed free cash flow ETFs have emerged as a popular choice among private equity investors, with 16 such ETFs collectively holding 350 million shares [10][12]. - These ETFs focus on companies with strong cash flow, reflecting their true profitability and financial health, which is increasingly appealing in the current market environment [11][12]. - The demand for stable, high-quality investment options has led to a growing interest in free cash flow ETFs, which offer both cash returns and growth potential [12].

"拿了快五年的医药主题基金终于开始赚钱了。"近日医药行情持续回暖，让很多投资者眼前一亮。随着 相关板块特别是创新药这一细分领域逐渐受到市场关注，多家公募基金公司纷纷开始宣推医药主题基 金，多位医药基金经理频频亮相发声。 在公募机构人士看来，医药行情回暖并不是短期市场情绪推动那么简单。经历近五年的调整后，原先制 约医药板块表现的多个负面因素正逐渐消退。医药板块，特别是创新药领域涌现出许多新变化。多位基 金经理表示，看好后续医药板块尤其是创新药细分领域的投资机会。 ● 本报记者 张韵 医药主题基金水涨船高 近期，医药板块行情持续回暖，多只医药主题基金也收获了不同程度的涨幅。 以被动产品为例，主投医药尤其是港股医药品种的ETF近期表现突出。5月20日，多只港股创新药ETF 跳空高开，截至当日收盘，全市场涨幅前十的ETF中有8只为港股创新药产品，涨幅全部超过4%。5月 23日，创新药ETF再度领涨，一只创新药产品位居全市场ETF涨幅榜首位。5月27日，医药主题ETF再度 领涨，港股创新药ETF占据全市场ETF涨幅前六位置。 Wind数据显示，截至5月28日，今年以来全市场涨幅前十的ETF均为主投港股医药的产品，涨幅均 ...

Group 1: Fund News - Minsheng Jianyin Fund announced the appointment of Zhu Yongming as the new deputy general manager on May 26, with Ding Hui taking over as the board secretary [1] - Over 80 funds have issued premium risk warnings since May, primarily affecting ETFs investing in markets such as the US, Saudi Arabia, and Germany [1][2] - Several fund companies have terminated cooperation with Minsheng Fund Sales (Shanghai) Co., Ltd., including Dongwu, Yin Hua, and Hua Tai Bai Rui [1] - Dongfanghong Asset Management plans to invest 10 million yuan in its core value mixed securities investment fund [1] Group 2: Notable Fund Manager Insights - Baoying Fund Manager Yao Yi expressed a long-term positive outlook on the growth potential of the innovative drug sector, suggesting investors adopt a longer-term perspective on investment value [2] - Yao Yi noted that while innovative drug stocks have rebounded significantly this year, a technical adjustment may occur after 3 to 4 months of accumulation, but the fundamental trends of the industry remain unchanged [2] Group 3: ETF Market Review - The market experienced fluctuations, with the Shanghai Composite Index down 0.18%, the Shenzhen Component down 0.61%, and the ChiNext Index down 0.68%, with total trading volume at 998.9 billion yuan, a decrease of 11 billion yuan from the previous trading day [3] - The Hong Kong Stock Connect innovative drug ETFs showed strong performance, with the highest increase of 3.88% [3][4] Group 4: Upcoming Fund Focus - The upcoming fund "Postal Savings Bank CSI Interbank Certificate of Deposit AAA Index 7-Day Holding" is an index-type fixed income fund managed by Wu Zhixiao, with a performance benchmark linked to the CSI Interbank Certificate of Deposit AAA Index [6]

Core Viewpoint - The innovative drug sector in China is experiencing significant growth, driven by favorable policies and market dynamics, with expectations for a long-term investment opportunity starting in 2025 [9][10][11]. Group 1: Factors Driving Growth - The innovative drug sector has seen a remarkable performance in 2023, with several thematic funds returning over 40%, and some exceeding 60% [9]. - The sector is expected to enter a revenue growth phase in 2025, with 80% of A-share and Hong Kong-listed innovative drug companies anticipated to see revenue increases following 2024's medical insurance negotiations [10]. - The transition from a reliance on basic medical insurance to a dual-driven model of commercial insurance and medical insurance is expected to enhance the valuation of innovative drug companies [10][11]. Group 2: Investment Opportunities - The current period is viewed as an optimal window for investing in innovative drugs, with a long investment cycle anticipated starting in 2025 [11]. - The innovative drug sector is expected to outperform other segments of the pharmaceutical industry, which are facing declines in performance and valuation [13]. - The Chinese innovative drug companies are now in the first tier globally, particularly in the competitive oncology field, with potential for leading advantages in the next few years [12]. Group 3: Investment Strategies - Investment strategies should focus on the product cycle, growth potential of the sector, and competitive landscape, prioritizing companies with high research barriers and leading global data [15]. - A "three-cycle resonance" strategy is recommended, analyzing industry trends, financial performance, and market cycles to identify companies with significant growth potential [16]. - The "bright line-dark line" framework can be utilized to capture structural opportunities, focusing on both common investment strategies and unique insights into market dynamics [17].

Group 1: Innovation Drugs and Gold ETFs Performance - Innovation drug-themed ETFs have shown significant growth, with the top two funds, WanKe ZhongZheng HongKong Innovation Drug ETF and JingShun ChangCheng HongKong Innovation Drug ETF, reporting net value increases of 9.02% and 9.01% respectively [2] - Other innovation drug ETFs also performed well, with several exceeding an 8% increase in net value [2] - The ASCO annual meeting, scheduled for May 30 to June 3, will showcase research results from companies like BeiGene and Kelun Biotech, which is expected to attract attention from the pharmaceutical industry and investors [2] - Gold-themed ETFs also performed strongly, with six funds reporting net value increases exceeding 6% [2] Group 2: Gold Price Trends - COMEX gold prices increased by 5.35%, while London gold saw a rise of 4.86%, and SHFE gold rose by over 4% [3] - Short-term adjustments in gold prices may occur, but long-term demand for inflation hedging and safe-haven assets is expected to support gold prices [3] Group 3: Fund Flows into Defense and Military ETFs - A total of 31 ETFs saw net inflows exceeding 100 million yuan, with significant inflows into military-themed ETFs such as Huaxia Shanghai Stock Exchange Science and Technology Innovation Board 50 ETF and Fuguo Zhongzheng Military Leader ETF, each exceeding 900 million yuan [4] - The military industry is anticipated to experience a turning point in orders, driven by new technologies and products aimed at enhancing equipment performance and reducing costs [4] Group 4: Support for Technology Enterprises - Recent policies from seven departments aim to enhance credit support for technology enterprises, with a focus on early-stage investments and long-term financing for hard technology [5] - The establishment of a bond market technology board is proposed to raise long-term, low-interest funds for technological innovation [5]